Home » Posts tagged with » AbbVie
MERU clinical trial : AbbVie ends Rova-T program in lung cancer

MERU clinical trial : AbbVie ends Rova-T program in lung cancer

Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]

AbbVie secures Rinvoq FDA approval for rheumatoid arthritis

Rinvoq FDA approval : US biopharma company AbbVie has bagged approval from the US Food and Drug Administration (FDA) for its 15mg, daily once oral, small molecule Janus kinase (JAK) inhibitor – Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis (RA). The FDA approval for Rinvoq is for the treatment of […]

Continue reading …
AbbVie to acquire Botox developer Allergan for $63bn

AbbVie acquisition of Allergan : US biopharma company AbbVie is all set to acquire Botox developer Allergan, an Irish pharma company, for $63 billion in a cash cum stock deal, as per pharma acquisition news. Headquartered in Chicago, AbbVie is engaged in developing drugs in areas such as immunology, oncology, neuroscience, and virology. On the […]

Continue reading …
Lupin out-licenses MALT1 inhibitor program to AbbVie in $977m deal

Indian pharma company Lupin has out-licensed its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US biopharma company AbbVie in a deal potentially worth around $977 million. Lupin and AbbVie have forged a partnership in this regard which gives the US biopharma company the exclusive global rights to develop and commercialize the […]

Continue reading …
Pfizer, AbbVie resolve IP matters for adalimumab biosimilar

Pfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters pertaining to the former’s proposed biosimilar of the latter’s rheumatoid arthritis drug Humira (adalimumab). Pfizer adalimumab biosimilar update As per the agreement terms, Pfizer has secured a non-exclusive patent license from AbbVie for the use […]

Continue reading …
Mylan launches Humira biosimilar Hulio across Europe

Mylan has launched Hulio, a biosimilar to AbbVie’s Humira (adalimumab), in major markets in Europe, a month after its approval from the European Commission for all indications of the reference product. Hulio will be available to patients as early as possible, said Mylan, which partnered with Fujifilm Kyowa Kirin Biologics in April to commercialize the […]

Continue reading …
Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial

German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase 3 trial in patients with moderate-to-severe chronic plaque psoriasis. Cyltezo succeeded in the NCT 02850965 phase 3 trial by not showing any clinically meaningful differences in efficacy, safety and immunogenicity […]

Continue reading …
Tolero, AbbVie to explore venetoclax alvocidib combo for AML

Tolero Pharmaceuticals said that its cyclin-dependent kinase 9 (CDK9) inhibitor alvocidib will be combined with AbbVie leukemia drug venetoclax to evaluate their potential in their treatment of relapsed/refractory acute myeloid leukemia (AML). In this regard, the two companies have entered into a clinical research collaboration while retaining full commercial rights for their respective drugs. According […]

Continue reading …
Hyrimoz EC approval : Novartis biosimilar of AbbVie Humira approved in EU

Hyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe for all indications of the reference drug including rheumatoid arthritis, Crohn’s disease, plaque psoriasis, uveitis and ulcerative colitis. The approval of Hyrimoz by European Commission (EC) was driven by analytical, preclinical and clinical research that […]

Continue reading …